What DeCODE Genetics does

deCODE Genetics is a population-scale human genetics research company headquartered in Reykjavik, Iceland, operating as a wholly-owned subsidiary of Amgen since December 2012. Founded in 1996 by Kári Stefánsson, the company runs what it describes as the most productive human gene discovery engine in the world, built on whole-genome sequencing, proprietary statistical algorithms, and bioinformatics infrastructure. Its defining resource is detailed genetic and medical data from more than 160,000 Icelandic volunteer participants—over half of Iceland's adult population—supplemented by genealogical records spanning over 1,000 years and integration with Iceland's universal healthcare system. Total discovery work extends across approximately 500,000 individuals globally, including cohorts in the US, UK, and Nordic and Baltic countries.

The company's core technology stack combines population-genetics methodology with advanced sequencing modalities (including Oxford Nanopore long-read and methylation analysis) and purpose-built AI tooling, most notably Spliceformer-45k, a transformer-based RNA splicing prediction model that outperforms the SpliceAI benchmark (PR-AUC 0.834 vs 0.820). Its functional outputs are peer-reviewed publications in Nature, Nature Genetics, Cell, and JAMA Cardiology, identifying genetic risk factors and rare variants for cardiovascular disease, cancer, neurological disorders, autoimmune diseases, and metabolic conditions.

Commercially, deCODE does not sell products or services; its single customer is Amgen, which uses deCODE's discoveries to identify and validate drug targets across its therapeutic pipeline. Revenue is internalized through Amgen's R&D budget rather than reported as a standalone line, and academic and healthcare collaborators (including the University of Iceland and Landspítali National Hospital) function as research partners rather than paying customers. The business is effectively a captive, vertically integrated human genetics research unit within Amgen.

Name

DeCODE Genetics

Legal name

deCODE genetics

Website

http://www.decode.com/

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

deCODE Genetics is a wholly-owned Amgen subsidiary headquartered in Reykjavik, Iceland, that operates a population-scale human gene discovery engine using whole-genome sequencing and proprietary AI to identify genetic risk factors and drug targets for Amgen's pipeline.

Ownership category

akta.pro rank

Product category

Population Genetics Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

akta.pro primary industry

Population Genomics & Preventive Precision Health Programs (HLAAANAL)

akta.pro secondary industries

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Public Health Genomics & Sequencing (WGS/Metagenomics) Networks (HLAJAIAK)

Keywords

• Human genetics research
• Population genomics analysis
• Gene discovery engine
• Genome sequencing research
• Drug target identification

Headquarters

HQ city

Reykjavík

HQ country

Iceland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Amgen subsidiary funding: As a wholly-owned subsidiary of Amgen since December 2012, deCODE genetics operates as an integrated part of Amgen's global research and development organization. The company conducts human genetics research to support Amgen's drug discovery and development programs, with funding provided through Amgen's R&D budget rather than generating independent revenue streams.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

deCODE genetics operates the world's most productive human gene discovery engine, correlating whole-genome sequence variation with phenotype and disease data across roughly 500,000 participants, including more than 160,000 Icelandic volunteers representing over half of Iceland's adult population. It discovers genetic risk factors for common diseases (cardiovascular, cancer, neurological, autoimmune and metabolic) and feeds validated targets into Amgen's drug discovery pipeline. The company does not sell commercial products or services; it conducts research and publishes findings in peer-reviewed journals.

Product overview

deCODE genetics is a population genetics research company and wholly-owned subsidiary of Amgen. The company does not offer commercial products or services in the traditional sense, but rather conducts human genetics research and gene discovery. Its core activities include analyzing whole genome sequence data from large population cohorts, identifying genetic risk factors for common diseases, and publishing research findings in peer-reviewed journals. Research focus areas include cardiovascular disease, cancer, neurological disorders (Alzheimer's, Parkinson's), autoimmune diseases, and reproductive health. The company leverages detailed genetic and medical information from participants, proprietary statistical algorithms, and genealogical databases to discover genetic variants associated with human disease.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Discovery of key genetic risk factors for dozens of common diseases including cardiovascular disease, cancer, neurological disorders, autoimmune diseases, and metabolic conditions
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

One partnership is on record.

• AmgencoreStrategic or Co-development Partner · 10 December 2012Amgen acquired deCODE genetics in December 2012 for its industry-leading ability to identify and validate disease targets in human populations. deCODE operates as a wholly-owned subsidiary and serves as Amgen's central human genetics research facility, enabling Amgen to develop medicines and carry out drug research aimed at tackling serious diseases and serving patients.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Ancestry: Consumer genomics company with very large consented genetic databases used for ancestry and trait/disease association research. Comparable to deCODE as a population-scale human genetics data platform, though focused on consumer genealogy rather than pharma drug-target discovery.
• 23andMe: Population-scale human genetics company with one of the largest consented genotype-phenotype databases (millions of customers). Comparable to deCODE in building large-scale genotype-phenotype resources for discovery, though focused on consumer/DTC channels rather than pharma integration.
• Human Longevity Inc. Founded by Craig Venter to apply whole-genome sequencing, microbiome, and phenotype data at population scale to drive discovery. Highly comparable to deCODE's population-genomics, WGS-first approach and emphasis on correlating rare variants with disease phenotypes.
• Regeneron Genetics Center: Pharma-integrated human genetics research arm (within Regeneron) that sequences and phenotypes large patient cohorts to fuel drug-target discovery. Closest analogue to deCODE: deep pharma backing, large proprietary sequencing programs, and a track record of translating genetic findings into therapeutic programs.

Broad incumbents

• Illumina: Dominant provider of next-generation sequencing platforms and consumables used by virtually every population-genomics program including deCODE. Comparable as a foundational enabler of deCODE's WGS-based discovery engine, with some overlapping population-genomics initiatives (e.g., Illumina's population sequencing efforts).
• Myriad Genetics: Established clinical genetics company with a portfolio of germline and somatic tests across oncology, women's health, and mental health. Comparable to deCODE in human genetics expertise, though Myriad focuses on commercialized clinical diagnostic tests rather than population-scale drug-target discovery for a single pharma owner.

Emerging players

• Helix: Population genomics company operating a CLIA/CAP sequencing lab and a population health platform for health systems and research partners. Comparable to deCODE as a population-genomics platform, though Helix is more commercially focused on clinical/research sequencing services than on pharma target discovery.
• Nebula Genomics: Personal genomics company using whole-genome sequencing with privacy-preserving techniques and decentralized data ownership to build a discovery cohort. Comparable to deCODE in emphasizing WGS over genotyping and integrating privacy-preserving data architectures.

Regional players

• Genomics England: UK government-backed initiative running large-scale whole-genome sequencing programs (e.g., 100,000 Genomes Project) and linking sequence data to NHS health records. Comparable to deCODE in leveraging a national-population, healthcare-linked genomics resource for discovery, but operating as a public-sector program in the UK.

Others

• UK Biobank: Large-scale population-based biomedical resource with deep genetic and phenotypic data on ~500,000 UK participants, widely used for gene-disease association studies. Comparable to deCODE as a foundational population-genomics resource feeding pharma and academic discovery, though structured as a public research resource rather than a corporate entity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/decodegenetics
• LinkedInlinkedin.com/company/decode-genetics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeCODE Genetics